QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Forecast, Price & News

$0.29
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$0.29
▼
$0.32
50-Day Range
$0.26
▼
$0.37
52-Week Range
$0.20
▼
$2.08
Volume
141,368 shs
Average Volume
526,146 shs
Market Capitalization
$8.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Adial Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
929.2% Upside
$3.00 Price Target
Short Interest
Healthy
1.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.28) to ($0.22) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ADIL stock logo

About Adial Pharmaceuticals (NASDAQ:ADIL) Stock

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson & William B. Stilley in November 2010 and is headquartered in Charlottesville, VA.

Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Stock News Headlines

June 1, 2023 | finance.yahoo.com
Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
May 28, 2023 | americanbankingnews.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 22.0% in May
June 6, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
May 24, 2023 | americanbankingnews.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Forecasted to Earn Q2 2023 Earnings of ($0.09) Per Share
May 13, 2023 | americanbankingnews.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update
May 12, 2023 | finanznachrichten.de
Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 | finance.yahoo.com
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 | finance.yahoo.com
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
June 6, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
May 10, 2023 | finance.yahoo.com
Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business
April 8, 2023 | americanbankingnews.com
Analysts Offer Predictions for Adial Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:ADIL)
April 7, 2023 | americanbankingnews.com
Adial Pharmaceuticals, Inc. Expected to Post Q1 2023 Earnings of ($0.14) Per Share (NASDAQ:ADIL)
April 4, 2023 | finance.yahoo.com
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
March 31, 2023 | finanznachrichten.de
Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
March 31, 2023 | americanbankingnews.com
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Expands By 42.2%
March 30, 2023 | finance.yahoo.com
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
March 30, 2023 | finance.yahoo.com
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
March 21, 2023 | finance.yahoo.com
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
March 8, 2023 | finance.yahoo.com
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
March 8, 2023 | finance.yahoo.com
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
March 7, 2023 | msn.com
ADIL Soars after Positive Regulatory Update
March 6, 2023 | markets.businessinsider.com
Adial Pharma Surges 80% On Update Of AD04
March 6, 2023 | finance.yahoo.com
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
March 2, 2023 | finance.yahoo.com
Adial Pharmaceuticals Schedules Business Update Conference Call
March 1, 2023 | stockhouse.com
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
February 28, 2023 | finance.yahoo.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near?
February 27, 2023 | finance.yahoo.com
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
See More Headlines

ADIL Price History

ADIL Company Calendar

Last Earnings
3/30/2023
Today
6/06/2023
Next Earnings (Estimated)
8/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADIL
CUSIP
N/A
CIK
1513525
Web
www.adialpharma.com
Phone
(434) 422-9800
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+933.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,730,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-281.54%
Return on Assets
-179.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.65
Quick Ratio
1.65

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.13 per share
Price / Book
2.23

Miscellaneous

Outstanding Shares
28,520,000
Free Float
22,466,000
Market Cap
$8.28 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Cary J. Claiborne
    President, Chief Executive Officer & Director
  • Joseph Truluck
    Chief Financial Officer, Secretary & Treasurer
  • Bankole A. JohnsonBankole A. Johnson
    Chief Medical Officer
  • Julien Dimastromatteo
    Vice President-Research
  • Alex Lugovoy
    Chief Business Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ADIL Stock - Frequently Asked Questions

Should I buy or sell Adial Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADIL shares.
View ADIL analyst ratings or view top-rated stocks.

What is Adial Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued twelve-month target prices for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 933.4% from the stock's current price.
View analysts price targets for ADIL or view top-rated stocks among Wall Street analysts.

How have ADIL shares performed in 2023?

Adial Pharmaceuticals' stock was trading at $0.2150 on January 1st, 2023. Since then, ADIL shares have increased by 35.0% and is now trading at $0.2903.
View the best growth stocks for 2023 here.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 324,800 shares, a decrease of 22.0% from the April 30th total of 416,400 shares. Based on an average daily volume of 671,600 shares, the days-to-cover ratio is currently 0.5 days.
View Adial Pharmaceuticals' Short Interest.

When is Adial Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 15th 2023.
View our ADIL earnings forecast.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Manchester Capital Management LLC (4.22%), Susquehanna International Group LLP (0.78%), Renaissance Technologies LLC (0.35%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $0.29.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $8.28 million. The company earns $-12,730,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com.

This page (NASDAQ:ADIL) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -